| Interactions between Xenobiotics and DME (XEOTIC)
|
| Fungicide(s), Herbicide(s) or Insecticide(s) |
|---|
| Fungicide |
Click to Show/Hide the Full List of Xenobiotics: 8 Xenobiotics
|
| Azoxystrobin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00938
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Fungicide |
| DME Modulation |
Azoxystrobin up-regulates the expression of DME CYP3A4 |
[1] |
| Cyproconazole |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00942
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Fungicide |
| DME Modulation |
Cyproconazole induces the drug-metabolizing activity of DME CYP3A4 |
[1], [2] |
| Enilconazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00944
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Fungicide |
| DME Modulation |
Enilconazole inhibits the drug-metabolizing activity of DME CYP3A4 |
[3] |
| Epoxiconazole |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00945
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Fungicide |
| DME Modulation |
Epoxiconazole induces the drug-metabolizing activity of DME CYP3A4 |
[1] |
| Flutolanil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00949
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Fungicide |
| DME Modulation |
Flutolanil up-regulates the expression of DME CYP3A4 |
[4] |
| Fluxapyroxad |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00950
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Fungicide |
| DME Modulation |
Fluxapyroxad up-regulates the expression of DME CYP3A4 |
[1] |
| Propiconazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00956
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Fungicide |
| DME Modulation |
Propiconazole inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 1.03992 microM) |
[5] |
| Tebuconazole |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00957
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Fungicide |
| DME Modulation |
Tebuconazole up-regulates the expression of DME CYP3A4 |
[6] |
| Herbicide |
Click to Show/Hide the Full List of Xenobiotics: 7 Xenobiotics
|
| Alachlor |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00967
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Herbicide |
| DME Modulation |
Alachlor up-regulates the expression of DME CYP3A4 |
[7] |
| Atrazine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00969
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Herbicide |
| DME Modulation |
Atrazine inhibits the drug-metabolizing activity of DME CYP3A4 |
[8] |
| Clofibric acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01257
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Herbicide |
| DME Modulation |
Clofibric acid induces the drug-metabolizing activity of DME CYP3A4 |
[9] |
| Dithiopyr |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00972
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Herbicide |
| DME Modulation |
Dithiopyr up-regulates the expression of DME CYP3A4 |
[4] |
| Diuron |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00973
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Herbicide |
| DME Modulation |
Diuron up-regulates the expression of DME CYP3A4 |
[10] |
| Isoproturon |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00975
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Herbicide |
| DME Modulation |
Isoproturon inhibits the drug-metabolizing activity of DME CYP3A4 |
[11] |
| Pretilachlor |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00978
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Herbicide |
| DME Modulation |
Pretilachlor up-regulates the expression of DME CYP3A4 |
[12] |
| Pesticide/Insecticide |
Click to Show/Hide the Full List of Xenobiotics: 25 Xenobiotics
|
| Benfuracarb |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01039
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Benfuracarb induces the drug-metabolizing activity of DME CYP3A4 |
[10] |
| Bifenthrin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01040
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Bifenthrin up-regulates the expression of DME CYP3A4 |
[13] |
| Bioallethrin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00910
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Bioallethrin up-regulates the expression of DME CYP3A4 |
[13] |
| Bioresmethrin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01041
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Bioresmethrin up-regulates the expression of DME CYP3A4 |
[13] |
| Carbofuran |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01597
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Carbofuran induces the drug-metabolizing activity of DME CYP3A4 |
[10] |
| Chlordecone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01598
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Chlordecone induces the drug-metabolizing activity of DME CYP3A4 |
[14] |
| Chlorfluazuron |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01043
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Chlorfluazuron up-regulates the expression of DME CYP3A4 |
[10] |
| Cyfluthrin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01045
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Cyfluthrin up-regulates the expression of DME CYP3A4 |
[13] |
| Cyhalothrin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01600
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Cyhalothrin inhibits the drug-metabolizing activity of DME CYP3A4 |
[8] |
| Cypermethrin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01046
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Cypermethrin inhibits the drug-metabolizing activity of DME CYP3A4 |
[11], [15] |
| Decamethrin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01047
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Decamethrin inhibits the drug-metabolizing activity of DME CYP3A4 |
[16] |
| Dichlorodiphenyl dichloroethane |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01048
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Dichlorodiphenyl dichloroethane up-regulates the expression of DME CYP3A4 |
[17] |
| Dieldrin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01051
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Dieldrin induces the drug-metabolizing activity of DME CYP3A4 |
[14] |
| Endosulfan |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01074
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Endosulfan inhibits the drug-metabolizing activity of DME CYP3A4 |
[18] |
| Fenitrothion |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01052
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Fenitrothion inhibits the drug-metabolizing activity of DME CYP3A4 |
[8] |
| Fenvalerate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01053
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Fenvalerate inhibits the drug-metabolizing activity of DME CYP3A4 |
[15] |
| Fonofos |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01054
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Fonof DMEos inhibits the drug-metabolizing activity of DME CYP3A4 |
[16] |
| Monocrotophos |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01062
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Monocrotophos up-regulates the expression of DME CYP3A4 |
[19] |
| Nonachlor |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01604
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Nonachlor induces the drug-metabolizing activity of DME CYP3A4 |
[20] |
| Parathion |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01064
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Parathion up-regulates the expression of DME CYP3A4 |
[21] |
| Pentachlorophenol |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01605
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Pentachlorophenol up-regulates the expression of DME CYP3A4 |
[22] |
| Phenthoate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01065
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Phenthoate inhibits the drug-metabolizing activity of DME CYP3A4 |
[23] |
| Profenofos |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01068
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Profenofos induces the drug-metabolizing activity of DME CYP3A4 |
[24] |
| Pyrethrins |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01069
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Pyrethrins up-regulates the expression of DME CYP3A4 |
[25] |
| Tebufenozide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01070
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Pesticide/Insecticide |
| DME Modulation |
Tebufenozide up-regulates the expression of DME CYP3A4 |
[26] |
| Health or Environmental Toxicant(s) |
|---|
| Acute Toxic Substance |
Click to Show/Hide the Full List of Xenobiotics: 9 Xenobiotics
|
| 1,4-naphthoquinone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01089
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Acute Toxic Substance |
| DME Modulation |
1,4-naphthoquinone up-regulates the expression of DME CYP3A4 |
[27] |
| 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01119
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Acute Toxic Substance |
| DME Modulation |
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine up-regulates the expression of DME CYP3A4 |
[28] |
| Allyl isothiocyanate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00852
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Allyl isothiocyanate inhibits the drug-metabolizing activity of DME CYP3A4 |
[29] |
| Chlorpyrifos |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01248
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Chlorpyrifos inhibits the drug-metabolizing activity of DME CYP3A4 |
[8] |
| Cycloheximide |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01268
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Cycloheximide inhibits the expression of DME CYP3A4 |
[30] |
| Fipronil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01302
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Fipronil up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[31] |
| Kaempferol |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01353
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Kaempferol inhibits the drug-metabolizing activity of DME CYP3A4 |
[32], [33] |
| Ochratoxin A |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01407
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Ochratoxin A inhibits the drug-metabolizing activity of DME CYP3A4 |
[34] |
| Salinomycin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01467
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Acute Toxic Substance |
| DME Modulation |
Salinomycin inhibits the drug-metabolizing activity of DME CYP3A4 |
[35] |
| Biotoxin |
Click to Show/Hide the Full List of Xenobiotics: 4 Xenobiotics
|
| Bufogenin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00788
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Biotoxin |
| DME Modulation |
Bufogenin induces the drug-metabolizing activity of DME CYP3A4 |
[36] |
| Cylindrospermopsin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00905
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Cyanotoxin |
| DME Modulation |
Cylindrospermopsin inhibits the drug-metabolizing activity of DME CYP3A4 |
[37] |
| 8-prenylnaringenin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01179
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Cytotoxin |
| DME Modulation |
8-prenylnaringenin inhibits the drug-metabolizing activity of DME CYP3A4 |
[38] |
| Leptomycin B |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00906
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Cytotoxin |
| DME Modulation |
Leptomycin B up-regulates the expression of DME CYP3A4 |
[39] |
| Carcinogen |
Click to Show/Hide the Full List of Xenobiotics: 4 Xenobiotics
|
| Benzo(a)pyrene |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00898
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Carcinogen |
| DME Modulation |
Benzo(a)pyrene up-regulates the expression of DME CYP3A4 |
[40] |
| Methylcholanthrene |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00899
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Carcinogen |
| DME Modulation |
Methylcholanthrene inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 > 10 microM) |
[41] |
| Aflatoxin B1 |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00806
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Carcinogen-mycotoxin |
| DME Modulation |
Aflatoxin B1 inhibits the drug-metabolizing activity of DME CYP3A4 |
[42] |
| Aflatoxin M1 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00816
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Carcinogen-mycotoxin |
| DME Modulation |
Aflatoxin M1 up-regulates the expression of DME CYP3A4 |
[43] |
| Environmental Pollutant |
Click to Show/Hide the Full List of Xenobiotics: 5 Xenobiotics
|
| Diazinon |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01274
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Environmental Pollutant |
| DME Modulation |
Diazinon up-regulates the expression of DME CYP3A4 |
[44] |
| Dichlorodiphenyl dichloroethylene |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00768
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Environmental Pollutant |
| DME Modulation |
Dichlorodiphenyl dichloroethylene up-regulates the expression of DME CYP3A4 |
[17] |
| Etoxazole |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01295
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Environmental Pollutant |
| DME Modulation |
Etoxazole up-regulates the expression of DME CYP3A4 |
[4] |
| Oxadiazon |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01416
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Environmental Pollutant |
| DME Modulation |
Oxadiazon induces the drug-metabolizing activity of DME CYP3A4 |
[45] |
| Polychlorinated dibenzodioxin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00917
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Environmental Pollutant |
| DME Modulation |
Polychlorinated dibenzodioxin induces the drug-metabolizing activity of DME CYP3A4 |
[46] |
| Health Hazard/Toxicant |
Click to Show/Hide the Full List of Xenobiotics: 11 Xenobiotics
|
| Chlordan |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01245
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Health and Environmental Toxicant |
| DME Modulation |
Chlordan induces the drug-metabolizing activity of DME CYP3A4 |
[14] |
| Perfluorooctane sulfonic acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00921
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Health and Environmental Toxicant |
| DME Modulation |
Perfluorooctane sulfonic acid up-regulates the expression of DME CYP3A4 |
[47] |
| 3-methylquercetin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01141
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Health Hazard |
| DME Modulation |
3-methylquercetin up-regulates the expression of DME CYP3A4 |
[48] |
| Alpha-linolenic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00873
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Health Hazard |
| DME Modulation |
Alpha-linolenic acid inhibits the drug-metabolizing activity of DME CYP3A4 |
[49] |
| Diethylhexyl phthalate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01004
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Health Hazard |
| DME Modulation |
Diethylhexyl phthalate induces the drug-metabolizing activity of DME CYP3A4 |
[50] |
| Galactosamine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00795
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Health Hazard |
| DME Modulation |
Galactosamine inhibits the expression of DME CYP3A4 |
[51] |
| Isosafrole |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00986
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Health Hazard |
| DME Modulation |
Isosafrole induces the drug-metabolizing activity of DME CYP3A4 |
[52] |
| Lead |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01505
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Health Hazard |
| DME Modulation |
Lead up-regulates the expression of DME CYP3A4 |
[53] |
| Medazepam |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00881
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Health Hazard |
| DME Modulation |
Medazepam up-regulates the expression of DME CYP3A4 |
[54] |
| Pirinixic acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01433
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Health Hazard |
| DME Modulation |
Pirinixic acid up-regulates the expression of DME CYP3A4 |
[55] |
| Tris(1,3-dichloro-2-propyl)phosphate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01031
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Health Hazard |
| DME Modulation |
Tris(1,3-dichloro-2-propyl)phosphate up-regulates the expression of DME CYP3A4 |
[56], [57] |
| Natural Product(s), Extract(s) or Medicine(s) |
|---|
| Natural Mixture |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Cyclodextrins |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00857
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Mixture |
| DME Modulation |
Cyclodextrins inhibits the drug-metabolizing activity of DME CYP3A4 |
[58] |
| Natural Product |
Click to Show/Hide the Full List of Xenobiotics: 34 Xenobiotics
|
| 5-hydroxyflavone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01161
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
5-hydroxyflavone inhibits the drug-metabolizing activity of DME CYP3A4 |
[33] |
| 6',7'-dihydroxybergamottin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01166
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
6',7'-dihydroxybergamottin inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.81 microM) |
[59] |
| 7-hydroxyflavone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01176
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
7-hydroxyflavone inhibits the drug-metabolizing activity of DME CYP3A4 |
[33] |
| 9-cis-retinal |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01181
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
9-cis-retinal induces the drug-metabolizing activity of DME CYP3A4 |
[60] |
| Acacetin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01184
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Acacetin inhibits the drug-metabolizing activity of DME CYP3A4 |
[33] |
| Alpha-naphthoflavone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01192
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Alpha-naphthoflavone inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 > 10 microM) |
[61] |
| Apigenin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01203
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Apigenin inhibits the drug-metabolizing activity of DME CYP3A4 |
[33], [62] |
| Baicalein |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01212
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Baicalein inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 9.2 microM) |
[63] |
| BDE-99 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00925
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
BDE-99 up-regulates the expression of DME CYP3A4 |
[64] |
| Bergamottin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01527
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Bergamottin inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 2.42 microM) |
[65] |
| Bilirubin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00877
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Bilirubin up-regulates the expression of DME CYP3A4 |
[66] |
| Chrysin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00878
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Chrysin inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 > 50 microM) |
[67] |
| Cinobufagin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00864
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Cinobufagin up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[36] |
| Clove oil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01531
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Clove oil up-regulates the expression of DME CYP3A4 |
[68] |
| Cryptotanshinone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01534
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Cryptotanshinone induces the drug-metabolizing activity of DME CYP3A4 |
[69] |
| Eupatorin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01541
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Eupatorin inhibits the drug-metabolizing activity of DME CYP3A4 |
[70] |
| Flavone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01304
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Flavone inhibits the drug-metabolizing activity of DME CYP3A4 |
[33] |
| Galangin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01308
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Galangin inhibits the drug-metabolizing activity of DME CYP3A4 |
[33] |
| Germacrone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01313
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Germacrone inhibits the drug-metabolizing activity of DME CYP3A4 |
[71] |
| Ginkgolide B |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00859
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Ginkgolide B up-regulates the expression of DME CYP3A4 |
[72], [73] |
| Hyperforin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01335
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Hyperforin inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 2.3 microM) |
[74] |
| Inermin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01345
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Inermin inhibits the drug-metabolizing activity of DME CYP3A4 |
[62] |
| Isoxazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00786
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Isoxazole inhibits the drug-metabolizing activity of DME CYP3A4 |
[75] |
| Lemongrass oil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01557
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Lemongrass oil up-regulates the expression of DME CYP3A4 |
[68] |
| Limonin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01560
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Limonin inhibits the drug-metabolizing activity of DME CYP3A4 (Ki = 23.2 microM) |
[76] |
| Muscone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00790
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Muscone up-regulates the expression of DME CYP3A4 |
[77] |
| Naringin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01391
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Naringin inhibits the drug-metabolizing activity of DME CYP3A4 |
[78] |
| Peppermint oil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01571
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Peppermint oil up-regulates the expression of DME CYP3A4 |
[79] |
| Safrole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01583
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Safrole inhibits the drug-metabolizing activity of DME CYP3A4 |
[80] |
| Schizandrol B |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01469
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Schizandrol B up-regulates the expression of DME CYP3A4 |
[81] |
| Skatole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00777
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Skatole inhibits the expression of DME CYP3A4 |
[82] |
| Steviol |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00810
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Steviol inhibits the expression of DME CYP3A4 |
[83] |
| Tamarixetin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01479
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Tamarixetin up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[84] |
| Walrycin A |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01498
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Natural Product |
| DME Modulation |
Walrycin A up-regulates the expression of DME CYP3A4 |
[12] |
| Plant Extract |
Click to Show/Hide the Full List of Xenobiotics: 9 Xenobiotics
|
| Basil oil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01526
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Plant Extract |
| DME Modulation |
Basil oil up-regulates the expression of DME CYP3A4 |
[68] |
| Caraway oil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00759
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Plant Extract |
| DME Modulation |
Caraway oil up-regulates the expression of DME CYP3A4 |
[68] |
| Cinnamon oil, bark |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01530
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Plant Extract |
| DME Modulation |
Cinnamon oil, bark up-regulates the expression of DME CYP3A4 |
[68] |
| Coriander oil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01533
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Plant Extract |
| DME Modulation |
Coriander oil up-regulates the expression of DME CYP3A4 |
[68] |
| Ginkgo biloba extract |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01314
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Plant Extract |
| DME Modulation |
Ginkgo biloba extract inhibits the drug-metabolizing activity of DME CYP3A4 |
[85] |
| Guggulu extract |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01550
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Plant Extract |
| DME Modulation |
Guggulu extract up-regulates the expression of DME CYP3A4 |
[86] |
| Juniperus communis oil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01556
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Plant Extract |
| DME Modulation |
Juniperus communis oil up-regulates the expression of DME CYP3A4 |
[68] |
| Mangifera indica extract |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00826
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Plant Extract |
| DME Modulation |
Mangifera indica extract inhibits the drug-metabolizing activity of DME CYP3A4 |
[87], [88] |
| Volatile oil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01569
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Plant Extract |
| DME Modulation |
Volatile oil up-regulates the expression of DME CYP3A4 |
[89] |
| Traditional Medicine |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Shexiang baoxin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00862
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Traditional Medicine |
| DME Modulation |
Shexiang baoxin up-regulates the expression of DME CYP3A4 |
[90] |
| Pharmaceutical Agent(s) |
|---|
| Approved/Marketed Drug |
Click to Show/Hide the Full List of Xenobiotics: 156 Xenobiotics
|
| Acetaminophen |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00217
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Acetaminophen inhibits the drug-metabolizing activity of DME CYP3A4 |
[91] |
| Adefovir dipivoxil |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00745
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Adefovir dipivoxil inhibits the drug-metabolizing activity of DME CYP3A4 |
[92] |
| Alitretinoin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00167
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Alitretinoin induces the drug-metabolizing activity of DME CYP3A4 |
[60] |
| Amiodarone hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00277
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Amiodarone hydrochloride inhibits the drug-metabolizing activity of DME CYP3A4 |
[93] |
| Amprenavir |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00139
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Amprenavir inhibits the drug-metabolizing activity of DME CYP3A4 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 1 microM) |
[94] |
| Arsenic trioxide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00339
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Arsenic trioxide up-regulates the expression of DME CYP3A4 |
[95] |
| Atorvastatin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00340
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Atorvastatin inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 5.1 microM) |
[96] |
| Azacitidine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00102
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Azacitidine up-regulates the expression of DME CYP3A4 |
[97] |
| Azithromycin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00164
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Azithromycin inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 > 10 microM) |
[98] |
| Bosentan |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00148
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Bosentan up-regulates the expression of DME CYP3A4 |
[77], [99] |
| Budesonide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00235
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Budesonide up-regulates the expression of DME CYP3A4 |
[100] |
| Buprenorphine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00343
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Buprenorphine inhibits the drug-metabolizing activity of DME CYP3A4 |
[101] |
| Caffeine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00218
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Caffeine inhibits the drug-metabolizing activity of DME CYP3A4 |
[102] |
| Calcitriol |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00184
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Calcitriol up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[103] |
| Cannabidiol |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00173
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cannabidiol inhibits the drug-metabolizing activity of DME CYP3A4 |
[104] |
| Capsaicin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00178
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Capsaicin inhibits the drug-metabolizing activity of DME CYP3A4 |
[105] |
| Carbamazepine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00011
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Carbamazepine induces the drug-metabolizing activity of DME CYP3A4 |
[106] |
| Cefaclor |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00124
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cefaclor induces the drug-metabolizing activity of DME CYP3A4 |
[107] |
| Cefadroxil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00412
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cefadroxil induces the drug-metabolizing activity of DME CYP3A4 |
[107] |
| Cetirizine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00348
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cetirizine inhibits the drug-metabolizing activity of DME CYP3A4 |
[108] |
| Chloroquine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00238
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Chloroquine inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 349.94517 microM) |
[5] |
| Chlorpromazine hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00280
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Chlorpromazine hydrochloride inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 23.3 microM) |
[109] |
| Cholic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00158
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cholic acid inhibits the drug-metabolizing activity of DME CYP3A4 |
[110] |
| Cimetidine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00015
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cimetidine inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 15 microM) |
[111] |
| Ciprofloxacin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00349
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Ciprof DMEloxacin inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 > 10 microM) |
[112] |
| Cisapride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00350
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cisapride inhibits the drug-metabolizing activity of DME CYP3A4 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.3 microM) |
[113] |
| Cisplatin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00334
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cisplatin inhibits the drug-metabolizing activity of DME CYP3A4 |
[114] |
| Clarithromycin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00146
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Clarithromycin inhibits the drug-metabolizing activity of DME CYP3A4 (Ki = 5.49 microM) |
[76] |
| Clindamycin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00240
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Clindamycin up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[107] |
| Clotrimazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00017
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Clotrimazole inhibits the drug-metabolizing activity of DME CYP3A4 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.016 microM) |
[115] |
| Crizotinib |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00195
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Crizotinib up-regulates the expression of DME CYP3A4 |
[116] |
| Cyclophosphamide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00018
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cyclophosphamide up-regulates the expression of DME CYP3A4 |
[117] |
| Cyclosporine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00241
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Cyclosporine inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 > 10 microM) |
[118] |
| Deferoxamine mesylate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00286
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Deferoxamine mesylate inhibits the drug-metabolizing activity of DME CYP3A4 |
[119] |
| Desipramine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00022
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Desipramine inhibits the drug-metabolizing activity of DME CYP3A4 |
[115] |
| Dexamethasone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00088
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Dexamethasone induces the drug-metabolizing activity of DME CYP3A4 |
[120] |
| Diclofenac |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00352
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Diclof DMEenac inhibits the drug-metabolizing activity of DME CYP3A4 (Ki = 1640 microM) |
[76] |
| Dicloxacillin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00116
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Dicloxacillin up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[107] |
| Diethylstilbestrol |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00166
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Diethylstilbestrol induces the drug-metabolizing activity of DME CYP3A4 |
[121] |
| Dihydroergotamine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00105
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Dihydroergotamine inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 2.99916 microM) |
[5] |
| Diltiazem hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00288
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Diltiazem hydrochloride inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.1 microM) |
[122] |
| Dimethyl sulfoxide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00001
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Dimethyl sulfoxide up-regulates the expression of DME CYP3A4 |
[123] |
| Docetaxel |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00153
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Docetaxel up-regulates the expression of DME CYP3A4 |
[117] |
| Dopamine hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00290
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Dopamine hydrochloride inhibits the drug-metabolizing activity of DME CYP3A4 |
[11] |
| Econazole nitrate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00293
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Econazole nitrate inhibits the drug-metabolizing activity of DME CYP3A4 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.05 microM) |
[115] |
| Efavirenz |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00216
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Efavirenz inhibits the drug-metabolizing activity of DME CYP3A4 |
[124] |
| Erlotinib hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00157
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Erlotinib hydrochloride inhibits the drug-metabolizing activity of DME CYP3A4 |
[117] |
| Erythromycin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00111
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Erythromycin inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.19 microM) |
[125] |
| Estradiol |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00090
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Estradiol induces the drug-metabolizing activity of DME CYP3A4 |
[126] |
| Ethinyl estradiol |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00267
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Ethinyl estradiol inhibits the drug-metabolizing activity of DME CYP3A4 (Ki = 18 microM) |
[76] |
| Felodipine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00245
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Felodipine up-regulates the expression of DME CYP3A4 |
[127] |
| Fenofibric acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00138
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Fenofibric acid induces the drug-metabolizing activity of DME CYP3A4 |
[9] |
| Ferric citrate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00135
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Ferric citrate induces the drug-metabolizing activity of DME CYP3A4 |
[128] |
| Fluconazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00036
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Fluconazole inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 8 microM) |
[129], [130] |
| Fluphenazine hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00295
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Fluphenazine hydrochloride inhibits the drug-metabolizing activity of DME CYP3A4 |
[115] |
| Flutamide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00038
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Flutamide induces the drug-metabolizing activity of DME CYP3A4 |
[117] |
| Fluticasone furoate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00297
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Fluticasone furoate inhibits the drug-metabolizing activity of DME CYP3A4 |
[131] |
| Fluvastatin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00359
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Fluvastatin inhibits the drug-metabolizing activity of DME CYP3A4 |
[132] |
| Gemfibrozil |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00042
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Gemfibrozil induces the drug-metabolizing activity of DME CYP3A4 |
[9] |
| Griseofulvin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00161
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Griseofulvin induces the drug-metabolizing activity of DME CYP3A4 |
[107] |
| Hydrocortisone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00264
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Hydrocortisone up-regulates the expression of DME CYP3A4 |
[133], [134] |
| Hydrogen peroxide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00388
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Hydrogen peroxide induces the drug-metabolizing activity of DME CYP3A4 |
[135] |
| Ifosfamide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00046
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Ifosfamide up-regulates the expression of DME CYP3A4 |
[117] |
| Irinotecan hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00301
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Irinotecan hydrochloride inhibits the drug-metabolizing activity of DME CYP3A4 (Ki = 24 microM) |
[76] |
| Isoniazid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00224
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Isoniazid inhibits the drug-metabolizing activity of DME CYP3A4 (Ki = 36 microM) |
[76] |
| Isotretinoin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00186
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Isotretinoin induces the drug-metabolizing activity of DME CYP3A4 |
[60] |
| Isradipine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00049
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Isradipine up-regulates the expression of DME CYP3A4 |
[127] |
| Itraconazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00250
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Itraconazole inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.004 microM) |
[136] |
| Ivermectin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00244
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Ivermectin inhibits the drug-metabolizing activity of DME CYP3A4 |
[137], [11] |
| Ketamine hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00302
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Ketamine hydrochloride inhibits the expression of DME CYP3A4 and leads to decreasing the drug-metabolizing activity of this enzyme |
[138] |
| Ketoconazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00251
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Ketoconazole inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 < 0.062 microM) |
[139] |
| Lansoprazole |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00052
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Lansoprazole induces the drug-metabolizing activity of DME CYP3A4 |
[140] |
| Lindane |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00740
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Lindane induces the drug-metabolizing activity of DME CYP3A4 |
[14] |
| Lopinavir |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00838
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Lopinavir inhibits the drug-metabolizing activity of DME CYP3A4 (Ki = 0.41 microM) |
[76] |
| Loratadine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00055
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Loratadine inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 > 30 microM) |
[141] |
| Lovastatin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00262
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Lovastatin up-regulates the expression of DME CYP3A4 |
[142] |
| Malathion |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00056
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Malathion induces the drug-metabolizing activity of DME CYP3A4 |
[60] |
| Meclizine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00058
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Meclizine inhibits the drug-metabolizing activity of DME CYP3A4 |
[143] |
| Medroxyprogesterone acetate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00743
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Medroxyprogesterone acetate up-regulates the expression of DME CYP3A4 |
[144] |
| Menthol |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00416
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Menthol induces the drug-metabolizing activity of DME CYP3A4 |
[145] |
| Methotrexate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00366
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Methotrexate inhibits the drug-metabolizing activity of DME CYP3A4 |
[146] |
| Methoxsalen |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00062
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Methoxsalen inhibits the expression of DME CYP3A4 |
[147], [148] |
| Mibefradil |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00436
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Mibefradil inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.13 microM) |
[111] |
| Miconazole nitrate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00308
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Miconazole nitrate inhibits the drug-metabolizing activity of DME CYP3A4 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.1 microM) |
[115], [149] |
| Mifepristone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00127
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Mifepristone inhibits the drug-metabolizing activity of DME CYP3A4 (Ki = 4.7 microM) |
[76] |
| Mitotane |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00064
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Mitotane up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[150] |
| Moricizine hydrochloride |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00309
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Moricizine hydrochloride up-regulates the expression of DME CYP3A4 |
[151] |
| Nafcillin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00101
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Nafcillin induces the drug-metabolizing activity of DME CYP3A4 |
[152], [153] |
| Nelfinavir mesylate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00310
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Nelfinavir mesylate inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.55 microM) |
[111] |
| Nicardipine hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00311
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Nicardipine hydrochloride inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.38 microM) |
[109] |
| Niclosamide |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00405
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Niclosamide inhibits the expression of DME CYP3A4 |
[154], [155] |
| Nifedipine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00066
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Nifedipine up-regulates the expression of DME CYP3A4 |
[12] |
| Omeprazole |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00069
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Omeprazole up-regulates the expression of DME CYP3A4 |
[156], [157] |
| Orlistat |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00179
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Orlistat up-regulates the expression of DME CYP3A4 |
[158] |
| Oxiconazole nitrate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00315
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Oxiconazole nitrate up-regulates the expression of DME CYP3A4 |
[159], [160] |
| Paclitaxel |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00256
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Paclitaxel inhibits the drug-metabolizing activity of DME CYP3A4 |
[161] |
| Pantoprazole |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00373
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Pantoprazole up-regulates the expression of DME CYP3A4 |
[162] |
| Pazopanib |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00374
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Pazopanib up-regulates the expression of DME CYP3A4 |
[163] |
| Penicillin V |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00099
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Penicillin V up-regulates the expression of DME CYP3A4 |
[164] |
| Pentamidine isethionate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00317
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Pentamidine isethionate inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 > 100 microM) |
[165] |
| Permethrin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00123
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Permethrin up-regulates the expression of DME CYP3A4 |
[166] |
| Phenelzine sulfate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00318
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Phenelzine sulfate inhibits the drug-metabolizing activity of DME CYP3A4 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 2 microM) |
[167] |
| Phenobarbital |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00410
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Phenobarbital inhibits the drug-metabolizing activity of DME CYP3A4 |
[168] |
| Phenylbutazone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00071
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Phenylbutazone induces the drug-metabolizing activity of DME CYP3A4 |
[169] |
| Phenytoin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00232
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Phenytoin up-regulates the expression of DME CYP3A4 |
[169] |
| Pimecrolimus |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00243
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Pimecrolimus up-regulates the expression of DME CYP3A4 |
[170] |
| Pioglitazone hydrochloride |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00319
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Pioglitazone hydrochloride up-regulates the expression of DME CYP3A4 |
[170] |
| Posaconazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00170
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Posaconazole inhibits the drug-metabolizing activity of DME CYP3A4 in Human hepatocyte (IC50 = 0.05 microM) |
[171] |
| Prednisolone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00219
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Prednisolone up-regulates the expression of DME CYP3A4 |
[172] |
| Probenecid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00072
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Probenecid inhibits the expression of DME CYP3A4 |
[172], [12] |
| Progesterone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00094
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Progesterone up-regulates the expression of DME CYP3A4 |
[173] |
| Proguanil |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00431
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Proguanil inhibits the expression of DME CYP3A4 |
[174] |
| Pyrantel |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00429
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Pyrantel inhibits the drug-metabolizing activity of DME CYP3A4 |
[175] |
| Quinine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00180
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Quinine inhibits the expression of DME CYP3A4 |
[176] |
| Rifampin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00223
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Rifampin induces the drug-metabolizing activity of DME CYP3A4 |
[177], [178] |
| Rifapentine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00227
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Rifapentine up-regulates the expression of DME CYP3A4 |
[179] |
| Rifaximin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00272
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Rifaximin induces the drug-metabolizing activity of DME CYP3A4 |
[180] |
| Ritonavir |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00160
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Ritonavir inhibits the drug-metabolizing activity of DME CYP3A4 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.016 microM) |
[181] |
| Rosiglitazone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00380
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Rosiglitazone inhibits the drug-metabolizing activity of DME CYP3A4 |
[182] |
| Saquinavir mesylate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00322
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Saquinavir mesylate inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 1.5 microM) |
[111] |
| Simvastatin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00125
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Simvastatin up-regulates the expression of DME CYP3A4 |
[82] |
| Sulfamethazine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00423
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Sulfamethazine up-regulates the expression of DME CYP3A4 |
[183] |
| Sulfisoxazole acetyl |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00327
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Sulfisoxazole acetyl up-regulates the expression of DME CYP3A4 |
[184] |
| Tamoxifen |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00383
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Tamoxifen inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 > 30 microM) |
[141] |
| Teriflunomide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00749
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Teriflunomide up-regulates the expression of DME CYP3A4 |
[72], [48] |
| Thalidomide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00083
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Thalidomide up-regulates the expression of DME CYP3A4 |
[185] |
| Thiabendazole |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00084
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Thiabendazole up-regulates the expression of DME CYP3A4 |
[186], [187] |
| Thioridazine hydrochloride |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00330
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Thioridazine hydrochloride inhibits the drug-metabolizing activity of DME CYP3A4 |
[188] |
| Topiramate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00189
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Topiramate up-regulates the expression of DME CYP3A4 |
[189] |
| Tretinoin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00253
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Tretinoin inhibits the expression of DME CYP3A4 |
[189], [190] |
| Troglitazone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00086
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Troglitazone up-regulates the expression of DME CYP3A4 |
[191] |
| Troleandomycin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00231
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Troleandomycin up-regulates the expression of DME CYP3A4 |
[192], [193] |
| Valproic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00029
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Valproic acid inhibits the expression of DME CYP3A4 |
[194] |
| Verapamil |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00387
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Verapamil inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 12 microM) |
[109] |
| Vitamin D |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00747
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Vitamin D enhances drug efficacy by activating miR-627 to suppress the drug-metabolizing enzyme CYP3A4 |
[195] |
| Voriconazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00142
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Voriconazole inhibits the drug-metabolizing activity of DME CYP3A4 in Human hepatocyte (IC50 = 13 microM) |
[171] |
| Zafirlukast |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00087
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Approved by US FDA |
| DME Modulation |
Zafirlukast inhibits the expression of DME CYP3A4 |
[196] |
| Apatinib |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00452
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Apatinib inhibits the drug-metabolizing activity of DME CYP3A4 |
[197] |
| Asiaticoside |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00453
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Asiaticoside inhibits the drug-metabolizing activity of DME CYP3A4 |
[198] |
| Benidipine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00438
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Benidipine inhibits the drug-metabolizing activity of DME CYP3A4 |
[143] |
| Bifonazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00464
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Bifonazole inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.8 microM) |
[115] |
| Cinnamic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01252
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Cinnamic acid inhibits the drug-metabolizing activity of DME CYP3A4 |
[199] |
| Cyproterone acetate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00495
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Cyproterone acetate up-regulates the expression of DME CYP3A4 |
[134] |
| Daidzein |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00439
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Daidzein inhibits the drug-metabolizing activity of DME CYP3A4 |
[11] |
| Dihydroartemisinin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00454
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Dihydroartemisinin inhibits the drug-metabolizing activity of DME CYP3A4 |
[137] |
| Gestodene |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00499
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Gestodene inhibits the drug-metabolizing activity of DME CYP3A4 |
[200] |
| Ginkgolide A |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01315
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Ginkgolide A up-regulates the expression of DME CYP3A4 |
[72] |
| Linoleic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01367
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Linoleic acid inhibits the drug-metabolizing activity of DME CYP3A4 |
[49] |
| Lycopene |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00849
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Lycopene up-regulates the expression of DME CYP3A4 |
[134] |
| Melarsoprol |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00475
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Melarsoprol inhibits the drug-metabolizing activity of DME CYP3A4 |
[201], [202] |
| Methoxychlor |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00446
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Methoxychlor inhibits the expression of DME CYP3A4 |
[203] |
| Oleanolic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01411
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Oleanolic acid inhibits the expression of DME CYP3A4 |
[204] |
| Roxithromycin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00440
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Roxithromycin inhibits the drug-metabolizing activity of DME CYP3A4 |
[205] |
| Stevioside |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00448
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Stevioside up-regulates the expression of DME CYP3A4 |
[83] |
| Tanshinone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00486
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Tanshinone induces the drug-metabolizing activity of DME CYP3A4 |
[206] |
| Tocotrienol delta |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00456
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Tocotrienol delta up-regulates the expression of DME CYP3A4 |
[207], [208] |
| Drug in Phase 3 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 10 Xenobiotics
|
| Afimoxifene |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00610
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Afimoxifene inhibits the drug-metabolizing activity of DME CYP3A4 |
[209] |
| Corticosterone |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00569
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Corticosterone up-regulates the expression of DME CYP3A4 |
[210] |
| Curcumin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00683
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Curcumin inhibits the expression of DME CYP3A4 |
[211] |
| Diethyltoluamide |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00582
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Diethyltoluamide up-regulates the expression of DME CYP3A4 |
[212], [213] |
| FK-435 |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00640
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
FK-435 inhibits the drug-metabolizing activity of DME CYP3A4 |
[209] |
| Glycyrrhizic acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00559
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Glycyrrhizic acid induces the drug-metabolizing activity of DME CYP3A4 |
[214] |
| Resveratrol |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00568
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Resveratrol inhibits the drug-metabolizing activity of DME CYP3A4 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.6 microM) |
[215], [11] |
| SGX301 |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00579
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
SGX301 inhibits the drug-metabolizing activity of DME CYP3A4 |
[32] |
| Sulforafan |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01478
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Sulforafan inhibits the drug-metabolizing activity of DME CYP3A4 |
[62] |
| Vitamin E |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00547
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Vitamin E inhibits the expression of DME CYP3A4 |
[216], [170] |
| Drug in Phase 2 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 9 Xenobiotics
|
| Andrographolide |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00543
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
Andrographolide inhibits the expression of DME CYP3A4 |
[217] |
| Bisphenol A |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01226
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
Bisphenol A induces the drug-metabolizing activity of DME CYP3A4 |
[163] |
| Bisphenol B |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00588
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
Bisphenol B up-regulates the expression of DME CYP3A4 |
[218] |
| Bufalin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00665
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
Bufalin up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[36] |
| CI-1040 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00664
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
CI-1040 up-regulates the expression of DME CYP3A4 |
[79] |
| Ethanol |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00539
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
Ethanol induces the drug-metabolizing activity of DME CYP3A4 |
[128] |
| Genistein |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00557
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
Genistein inhibits the drug-metabolizing activity of DME CYP3A4 |
[33] |
| PD-0325901 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00667
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
PD-0325901 up-regulates the expression of DME CYP3A4 |
[219] |
| Phenethyl isothiocyanate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00596
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 2 |
| DME Modulation |
Phenethyl isothiocyanate inhibits the expression of DME CYP3A4 |
[220] |
| Drug in Phase 1 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 11 Xenobiotics
|
| Chitosan |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00621
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1/2 |
| DME Modulation |
Chitosan induces the drug-metabolizing activity of DME CYP3A4 |
[221] |
| Piperine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00635
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1/2 |
| DME Modulation |
Piperine induces the drug-metabolizing activity of DME CYP3A4 |
[222] |
| Butylated hydroxytoluene |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00601
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Butylated hydroxytoluene up-regulates the expression of DME CYP3A4 |
[223] |
| Carbendazim |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00598
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Carbendazim up-regulates the expression of DME CYP3A4 |
[10] |
| Epsilon-viniferin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00646
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Epsilon-viniferin inhibits the drug-metabolizing activity of DME CYP3A4 |
[224] |
| Flavanone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00738
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Flavanone inhibits the drug-metabolizing activity of DME CYP3A4 |
[33] |
| Licochalcone A |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01365
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Licochalcone A inhibits the drug-metabolizing activity of DME CYP3A4 |
[225] |
| Naringenin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00573
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Naringenin inhibits the drug-metabolizing activity of DME CYP3A4 |
[226] |
| Quercetin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00538
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Quercetin inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 2.11 microM) |
[141] |
| Sodium arsenite |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00632
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
Sodium arsenite induces the drug-metabolizing activity of DME CYP3A4 |
[227] |
| SR-12813 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00633
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 1 |
| DME Modulation |
SR-12813 induces the drug-metabolizing activity of DME CYP3A4 |
[228] |
| Preclinical/Patented Drug |
Click to Show/Hide the Full List of Xenobiotics: 14 Xenobiotics
|
| 1-aminobenzotriazole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01099
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
1-aminobenzotriazole inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.45 microM) |
[229] |
| 13-cis-retinal |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01094
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
13-cis-retinal induces the drug-metabolizing activity of DME CYP3A4 |
[60] |
| HET-0016 |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01396
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
HET-0016 inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 65.4 microM) |
[230] |
| Isoliquiritigenin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00710
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
Isoliquiritigenin inhibits the drug-metabolizing activity of DME CYP3A4 |
[62] |
| Mevastatin |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00700
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
Mevastatin up-regulates the expression of DME CYP3A4 |
[7] |
| Oleic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01412
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
Oleic acid inhibits the expression of DME CYP3A4 |
[204] |
| Perfluorododecanoic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00927
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
Perfluorododecanoic acid inhibits the expression of DME CYP3A4 |
[231] |
| Proadifen |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01438
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
Proadifen inhibits the expression of DME CYP3A4 |
[12] |
| YM-758 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00719
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
YM-758 up-regulates the expression of DME CYP3A4 |
[196] |
| Chir-99021 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00736
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Patented Pharmaceutical Agent |
| DME Modulation |
Chir-99021 up-regulates the expression of DME CYP3A4 |
[232] |
| GW-3965 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01325
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Patented Pharmaceutical Agent |
| DME Modulation |
GW-3965 up-regulates the expression of DME CYP3A4 |
[233] |
| L-754394 |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01361
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Patented Pharmaceutical Agent |
| DME Modulation |
L-754394 inhibits the drug-metabolizing activity of DME CYP3A4 (Ki = 7.5 microM) |
[76] |
| R-116010 |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01452
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Patented Pharmaceutical Agent |
| DME Modulation |
R-116010 inhibits the drug-metabolizing activity of DME CYP3A4 (IC50 = 0.35 microM) |
[234] |
| Ro-21-5104 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01456
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Patented Pharmaceutical Agent |
| DME Modulation |
Ro-21-5104 induces the drug-metabolizing activity of DME CYP3A4 |
[235] |
| Drug Marketed but Withdrawn from Market |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Sitaxsentan |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00522
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Drug Marketed but Withdrawn from Market |
| DME Modulation |
Sitaxsentan inhibits the expression of DME CYP3A4 |
[82] |
| Investigative Agent |
Click to Show/Hide the Full List of Xenobiotics: 20 Xenobiotics
|
| 1,5-benzothiazepine |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01090
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Investigative Agent |
| DME Modulation |
1,5-benzothiazepine up-regulates the expression of DME CYP3A4 |
[236] |
| 2-aminopyrimidine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00780
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
2-aminopyrimidine inhibits the drug-metabolizing activity of DME CYP3A4 |
[237] |
| 3,3',4,5'-tetrahydroxystilbene |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01133
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Investigative Agent |
| DME Modulation |
3,3',4,5'-tetrahydroxystilbene up-regulates the expression of DME CYP3A4 |
[238] |
| 3-ketolithocholic acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01138
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Investigative Agent |
| DME Modulation |
3-ketolithocholic acid up-regulates the expression of DME CYP3A4 |
[239] |
| 4-chlorophenylbiguanide |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01152
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
4-chlorophenylbiguanide inhibits the drug-metabolizing activity of DME CYP3A4 |
[137] |
| 5-methoxyindole |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01163
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
5-methoxyindole inhibits the drug-metabolizing activity of DME CYP3A4 |
[11] |
| 6,7-dihydroxyflavone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01167
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
6,7-dihydroxyflavone inhibits the drug-metabolizing activity of DME CYP3A4 |
[33] |
| Arachidonic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00876
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
Arachidonic acid inhibits the drug-metabolizing activity of DME CYP3A4 |
[49] |
| Avasimibe |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00804
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
Avasimibe up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[240] |
| Azamulin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01211
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
Azamulin inhibits the drug-metabolizing activity of DME CYP3A4 |
[241] |
| Beta-naphthoflavone |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01220
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Investigative Agent |
| DME Modulation |
Beta-naphthoflavone inhibits the expression of DME CYP3A4 |
[242] |
| CINPA1 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01292
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Investigative Agent |
| DME Modulation |
CINPA1 up-regulates the expression of DME CYP3A4 |
[243] |
| CITCO |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01165
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
CITCO induces the drug-metabolizing activity of DME CYP3A4 |
[244] |
| Deoxyelephantopin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01272
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
Deoxyelephantopin inhibits the drug-metabolizing activity of DME CYP3A4 |
[245] |
| DY-9760e |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01130
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
DY-9760e inhibits the drug-metabolizing activity of DME CYP3A4 |
[246] |
| Farnesol |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01298
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Investigative Agent |
| DME Modulation |
Farnesol up-regulates the expression of DME CYP3A4 |
[247] |
| Lithocholic acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00787
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Investigative Agent |
| DME Modulation |
Lithocholic acid up-regulates the expression of DME CYP3A4 |
[248], [249] |
| NSC-305787 |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01200
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
NSC-305787 induces the drug-metabolizing activity of DME CYP3A4 |
[250] |
| Phloxine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00792
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
Phloxine inhibits the drug-metabolizing activity of DME CYP3A4 |
[251] |
| Pregnenolone carbonitrile |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01437
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Investigative Agent |
| DME Modulation |
Pregnenolone carbonitrile up-regulates the expression of DME CYP3A4 |
[172] |
| Other Chemical Compound(s) or Element(s) |
|---|
| Cosmetic Additive |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| 2-acetyltributylcitrate |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01612
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Cosmetic Additive |
| DME Modulation |
2-acetyltributylcitrate induces the drug-metabolizing activity of DME CYP3A4 |
[50] |
| Chemical Compound |
Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
|
| Naphthalene |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO00764
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Chemical Compound |
| DME Modulation |
Naphthalene up-regulates the expression of DME CYP3A4 and leads to increasing the drug-metabolizing activity of this enzyme |
[252] |
| Phthalic acid |
Click to Show/Hide the Detail |
Induction |
| XEOTIC ID |
XEO01430
XEOTIC Info
|
Gene Form |
mRNA |
| Classification |
Chemical Compound |
| DME Modulation |
Phthalic acid up-regulates the expression of DME CYP3A4 |
[170] |
|
|
|
|
|
|
